ArticlePloS one2026

RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.

Laura de-la-Puente-Ovejero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.